$6.82-0.43 (-6.00%)
Eupraxia Pharmaceuticals Inc. (EPRX) is a Pharmaceuticals and Biotechnology company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for EPRX, including 3 press releases and news items and 3 SEC filings. The most recent was published Oct 22, 2026.
Price$6.82+0.29 (+4.36%)
2026-07-302026-10-30
News · 26 weeks37-20%
2026-05-102026-11-01
Mix2190d
- Other10(48%)
- SEC Filings9(43%)
- Earnings1(5%)
- Analyst1(5%)
Latest news
25 items- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst DayVANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will participate in the following upcoming conferences and host a virtual Analyst Day: Craig Hallum Biotech Catalyst Virtual Conference (October 22nd, 2026)Format: Fireside Chat & 1x1 MeetingsFireside Chat Date & Time: October 22, 2026, at 10:30am ETWebcast link: HereLocation: Virtual BIO-Europe (November
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic EsophagitisEupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a statistical team who are doing periodic reviews of the unblinded data to ensure that the statistical assumptions and sample size on efficacy are adequate and do not need to be revised. These reviews have confirmed that the sample size as designed does not need to be adjustedWithin both parts of the RESOLVE trial (open-label Phase 1b/2a and placebo-controlled Phase 2b), over 3,000 injections of EP-104GI or vehicle have been administered with no treatment-related Serious Adverse Events (SAEs)Interim analysis of the Phase 2b portion of the study is on t
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesVANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashvil
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisThe highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission1The second highest dose group of EP-104GI (Cohort 8b) continued to show meaningful histologic reduction in inflammation and fibrosis with Stage –0.26 and Grade –0.27 in EoEHSS at 36 weeksThe Cohort 8b and Cohort 9 responses are consistent with clinical and histologic responses seen across all cohorts analyzed to date; in total, 9 of 14 patients (64%) have remained in clinical remission 52 weeks after receiving a single administration of EP-104GI VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharm
- ANALYSTWedbush initiated coverage on Eupraxia Pharmaceuticals with a new price targetWedbush initiated coverage of Eupraxia Pharmaceuticals with a rating of Outperform and set a new price target of $17.00
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market. The Company also announced that members of its management team will participate in upcoming investor conferences. The Company’s common shares were previously listed on the Nasdaq Capital Market and will continue to trade under the ticker symbol "EPRX." Eupraxi
- SECSEC Form SUPPL filed by Eupraxia Pharmaceuticals Inc.SUPPL - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- SECSEC Form EFFECT filed by Eupraxia Pharmaceuticals Inc.EFFECT - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- SECAmendment: SEC Form F-10/A filed by Eupraxia Pharmaceuticals Inc.F-10/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis PatientsThe number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatmentIn the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepointsThe number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment At baseline 31% of patients in Cohorts 7-9 had severe dysphagia; no patients had severe dysphagia at 24 and 52 weeks post treatmentEP-104GI continues to be well
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals Reports Second Quarter 2026 Financial ResultsNew data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities. VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2026. All dollar values are
- SECSEC Form F-X filed by Eupraxia Pharmaceuticals Inc.F-X - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)
- SECSEC Form F-10 filed by Eupraxia Pharmaceuticals Inc.F-10 - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
- PREupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of GrowthVANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026. Dr. Millard brings nearly 25 years of leadership experience in technical operatio
- SECSEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)
EPRX FAQ
6 questionsWhat is the latest news on EPRX?
In the last 30 days Quantisnow tracked 6 wire items for EPRX: 3 press releases and news items and 3 SEC filings. The most recent was published on October 22, 2026.Where does EPRX stock trade?
Eupraxia Pharmaceuticals Inc. (EPRX) is listed on NASDAQ.What sector and industry is EPRX in?
Eupraxia Pharmaceuticals Inc. operates in the Health Care sector, Pharmaceuticals and Biotechnology industry.What are analysts saying about EPRX?
Eupraxia Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $17.00 price target on 2026-09-24. Recent price targets range from $11.00 to $25.00.What companies are similar to EPRX?
Notable peers in the same industry include IMV (IMV Inc.), NVCN (Neovasc Inc.), HEXO (HEXO Corp.), ZOM (Zomedica Corp.), RVLP (RVL Pharmaceuticals plc). Compare EPRX side-by-side with any of them on Quantisnow.How can I track EPRX on Quantisnow?
Quantisnow aggregates Eupraxia Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EPRX to receive live email and push alerts on every new disclosure.